Rapid Dose Therapeutics Announces Management Change

Rapid Dose Therapeutics Corp. today announced a management change in the Company.

Feb. 10, 2022 13:26 UTC

BURLINGTON, Ontario--(BUSINESS WIRE)-- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation today announced a management change in the Company.

The Board of Directors provided notice on February 9, 2022 of its intention not to renew Mr. Thomas Bryson’s employment agreement, which expires at the close of business on March 14, 2022. Mr. Bryson joined RDT in March 2021 with the amalgamation of his predecessor company Consolidated Craft Brands Inc. (“CCB”) and assisted in the integration of CCB into RDT within the terms of his one-year employment contract.

Mr. Bryson will continue as an employee of RDT until the end of his agreement, but was relieved of all duties and responsibilities as President of RDT at the close of business on February 9, 2022.

The Company wishes Mr. Bryson all the best in his future endeavours.

The management team led by the Company’s CEO Mark Upsdell continues to be supported by the leadership team including Doug Hyland, interim CFO, Jason Lewis, SVP Business Development and the Board of Directors.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.
www.rapid-dose.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contacts

Investor Contact:
Mark Upsdell, CEO
mupsdell@rapid-dose.com
416-477-1052

Media Contact:
Dara Willis
dara@dwcomm.ca
416-836-9272

Source: Rapid Dose Therapeutics Corp.

MORE ON THIS TOPIC